Innocan Pharma Corp. Stock
Price
Target price
€0.16
€0.16
-1.520%
-0.0025
-1.520%
€1.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Innocan Pharma Corp. Stock
A loss of -1.520% shows a downward development for Innocan Pharma Corp..
Our community is currently high on Innocan Pharma Corp. with 5 Buy predictions and 0 Sell predictions.
Based on the current price of 0.16 € the target price of 1 € shows a potential of 515.38% for Innocan Pharma Corp. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Innocan Pharma Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Innocan Pharma Corp. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting
Herzliya, Israel and Calgary, Alberta - July 2, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Herzliya, Israel and Calgary, Alberta - June 11, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million
Herzliya, Israel and Calgary, Alberta - May 27, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company